FindTrial
Sign In

A phase III, double blind, comparative study of KRN125

A double blind study of KRN125 compared to KRN8601 for chemotherapy-induced neutropenia in malignant lymphoma

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221357
Enrollment
Unknown
Registered
2011-01-21
Start date
2011-01-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced neutropenia

Interventions

investigational material(s) Generic name etc : KRN125 INN of investigational material : pegfilgrastim Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Adminis

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Diagnosed with Hodgkin's or non-Hodgkin's lymphoma - Going to receive CHASE treatment regimen - ECOG PS =< 2 - Appropriate bone marrow, hepatic and renal functions - Written informed consent

Exclusion criteria

Exclusion criteria: - Double cancer - Previous bone marrow or peripheral blood stem cell transplantation - More than 3 prior chemotherapies for salvage treatment regimen - Primary hematologic disease such as myelodysplastic syndrome or aplastic anemia - Undergoing interstitial pneumonia treatment - Previous radiotherapy within 4 weeks of enrollment

Design outcomes

Primary

MeasureTime frame
Efficacy: duration of severe neutropenia—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026